Enzyme-Activatable Probe for Tumor Bimodal Imaging, Intraoperative Navigation, and Urinalysis.

Authors

Meilin Xu, Yao Dong, Yu Wang, Xiaole Zhou, Leyu Wang

Published in

Advanced healthcare materials. Pages e71862. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

We develope an enzyme-activatable platform (NO₂-RGD-Gd) for the integrated urinary biomarker detection, highcontrast fluorescence-magnetic resonance (MR) dualmodal imaging, and real-time image-guided surgical navigation within a single molecule. The advantages, including the favorable tumor-targeting affinity (RGD peptide), high renal clearance efficiency, and tumor-specific fluorescence activation, are achieved by rationally engineering the molecular architecture. Benefiting from these characteristics, the NO₂-RGD-Gd effectively bridges the boundary between diagnosis and therapy, achieving outstanding combinatorial performance in in vivo applications. It allows early and precise diagnosis through urinary biomarkers, provides anatomical-pathological and molecular imaging information of tumor lesions via fluorescence-MR dual-modal imaging, and delineates tumor boundaries for accurate surgical navigation relying on tumor-targeted activatable fluorescence imaging signals. Furthermore, all these processes can be realized simply via intravenous injection, offering a more efficient and feasible strategy for integrated diagnostic and therapeutic applications.

PMID:
42885996
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.